<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392297</url>
  </required_header>
  <id_info>
    <org_study_id>RRPCEM_CMV</org_study_id>
    <nct_id>NCT04392297</nct_id>
  </id_info>
  <brief_title>Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals</brief_title>
  <official_title>To Identify the Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals and to Develop Methods for the Diagnosis and Treatment of Patients in This Category</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Republican Research and Practical Center for Epidemiology and Microbiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belarusian State Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Republican Research and Practical Center for Epidemiology and Microbiology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current study evaluates possible correlations between the content of various cell
      populations, the genetic material of the virus and antibodies to it in the blood of patients
      and the risk of thrombosis development in patients with acute CMV infection.

      –ê new method for the early detection of immunological and clinical signs of thromboembolic
      complications of CMV infection in immunocompetent individuals and the treatment of patients
      in this category will be developed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  evaluate the immune status main indicators that characterize the activation of immune
           system, immunosuppression and anergy (myeloid suppressor cells, T-regulatory cells,
           T-cells according to the stages of differentiation (naive - effector - memory),
           activated T-cells);

        -  identify and characterize immunological disorders in patients with CMV infection
           complicated by thromboembolism of various localization;

        -  determine the presence and quantitative content in plasma / serum and neutrophils of the
           CMV genetic material by real-time PCR;

        -  study humoral immunity to CMV (IgM / IgG antibodies to CMV in serum);

        -  determine the content of CMV specific T-cells in peripheral blood;

        -  develop a method for the early detection of immunological and clinical signs of
           thromboembolic complications of CMV infection in immunocompetent persons and treatment
           of patients in this category.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with thrombosis</measure>
    <time_frame>1 month</time_frame>
    <description>Thrombosis as a complication of CMV infection and its association with immune status, CMV specific T-cells count and CMV specific antibodies level</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>CMV</condition>
  <arm_group>
    <arm_group_label>Patients with CMV infection</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bood leukocyte subsets</intervention_name>
    <description>Determination of blood leukocyte subpopulations: myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells; circulating endothelial cells</description>
    <arm_group_label>Patients with CMV infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CMV specific T-cells</intervention_name>
    <description>CMV specific T-cells detected by flow cytometry</description>
    <arm_group_label>Patients with CMV infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum CMV IgM / IgG antibodies</intervention_name>
    <description>serum CMV IgM / IgG antibodies detected by ELISA</description>
    <arm_group_label>Patients with CMV infection</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Heparinized whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with CMV infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 - 80 years;

          -  fever of not clear etiology

          -  confirmed CMV infection

        Exclusion Criteria:

          -  HIV infection

          -  taking hormones, cytostatics;

          -  drug addiction

          -  malignant neoplasms over the past 5 years.

          -  active viral hepatitis or liver cirrhosis;

          -  immunosuppressive conditions of any etiology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Fomina, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of the laboratory, RSPCEM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Republican Research and Practical Center for Epidemiology and Microbiology</name>
      <address>
        <city>Minsk</city>
        <zip>220114</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 16, 2020</last_update_submitted>
  <last_update_submitted_qc>May 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytomegalovirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

